中国成人流行性感冒诊疗规范急诊专家共识

doi:10.3969/j.issn.1002-1949.2019.10.001

摘要
图/表
参考文献(113)
相关文章 (15)

全文: PDF (3206 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要流行性感冒（influenza，简称流感）是由流感病毒引起的一种急性呼吸道传染病，具有流行面广、传染性强及发病率高等特点，其波及范围之广、造成的经济损失位于传染性疾病之首。据估计，全球每年有291 243～645 832例病例死于季节性流感相关性呼吸道疾病。2010～2018年美国季节性流感期间，每年有430万～2300万例流感病例就诊，其中14万～96万例接受住院治疗；每年死于流感相关呼吸和循环系统疾病者为1.2万～7.9万例。2009～2010年中国新型甲型H1N1流感大流行期间，内地累计实验室确诊1 275 885例新型甲型H1N1流感病例，其中31 651例接受住院治疗，805例死亡。近年来我国发生了多起人感染H5N1和H7N9禽流感疫情。截至2018年7月，累计确诊1625例H7N9禽流感病例，其中623例死亡，病死率为38%。同时还有散发的人感染H9N2、H5N6和H10N8等禽流感报道，且多为重症病例，病死率极高。近年来国内外陆续发布了许多关于流感诊疗的指南与共识，但其中涉及流感急诊诊疗规范的内容则极少，特别是国内尚无急诊科流感诊疗的相关指南与共识。为此，中国医师协会急诊医师分会、中华医学会急诊医学分会和中国人民解放军急救医学专业委员会等组织国内急诊领域专家制定此共识，以期制定符合急诊医学特色的流感诊治指导性文件，进而提高急诊医师对流感的早期识别、早期诊断和早期治疗能力，降低流感对社会造成的巨大危害。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	中国医师协会急诊医师分会
	中华医学会急诊医学分会
	中国人民解放军急救医学专业委员会
	急救与创伤研究教育部重点实验室

作者简介: 于学忠，北京协和医院，E-mail：yxz@medmail.com.cn;陈玉国，山东大学齐鲁医院，E-mail：chen919085@126.com;赵晓东，中国人民解放军总医院第四医学中心，E-mail：zxd63715@126.com;吕传柱，急救与创伤研究教育部重点实验室，海南医学院，E-mail：lvchuanzhu677@126.com;陆一鸣，上海交通大学医学院附属瑞金医院， E-mail：lvyiming@rjh.com.cn。

引用本文:

中国医师协会急诊医师分会，中华医学会急诊医学分会，中国人民解放军急救医学专业委员会，急救与创伤研究教育部重点实验室. 中国成人流行性感冒诊疗规范急诊专家共识[J]. 中国急救医学, 2019, 39(10): 915-928.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2019.10.001 或 http://www.cnemergency.org.cn/CN/Y2019/V39/I10/915

［1］Loregian A, Mercorelli B, Nannetti G, et al. Antiviral strategies against influenza virus: towards new therapeutic apptoaches［J］. Cell Mol Life Sci, 2014, 71(19): 3659-3683.  ［2］Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study［J］. Lancet, 2018， 391(10127): 1285-3000.  ［3］Centers for Disease Control and Prevention. Disease Burden of Influenza.Available at: https://www.cdc.gov/flu/about/burden/index.html Accessed on November 8, 2018. ［4］徐翠玲，孙闪华，张彦平，等. 2009-2010年中国内地甲型H1N1流感确诊病例流行特征分析［J］. 疾病监测， 2011， 26(10): 780-784.  ［5］Mostafa A, Abdelwhab EM, Mettenleiter TC, et al. Zoonotic Potential of Influenza A Viruses: A Comprehensive Overview［J］. Viruses, 2018, 10(9). pii: E497. ［6］Zhang R, Chen T, Ou X, et al. Clinical, epidemiological and virological characteristics of the first detected human case of avian influenza A(H5N6) virus［J］. Infect Genet Evol, 2016, 40: 236-242.  ［7］Chen HY, Yuan H, Gao R, et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study［J］. Lancet, 2014, 383(9918): 714-721.  ［8］Jin Y, Yu D, Ren H, et al. Phylogeography of Avian influenza A H9N2 in China［J］. BMC Genomics, 2014, 15: 1110.  ［9］人禽流感专家组. 中国高致病性禽流感A/H5N1病毒感染病例临床管理专家共识(草案) ［J］. 中华结核和呼吸病学杂志， 2009， 32 (5): 329-334. ［10］国家卫生和计划生育委员会，国家中医药管理局. 流行性感冒诊疗方案(2018年版)［J］. 中国感染控制杂志， 2018， 17(2): 181-184.  ［11］卫生部流行性感冒诊断与治疗指南编撰专家组. 流行性感冒诊断与治疗指南(2011年版) ［J］．中华结核和呼吸杂志， 2011， 34(10): 725-734． ［12］Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices(ACIP)［J］. MMWR Recomm Rep, 2011, 60(1): 1-24.  ［13］国家卫生和计划生育委员会. 人感染H7N9禽流感诊疗方案(2017年第1版)［J］. 中国病毒病杂志， 2017， 7(1): 1-4.  ［14］中华医学会呼吸病学分会，中华医学会儿科学分会. 流行性感冒抗病毒药物治疗与预防应用中国专家共识［J］. 中华医学杂志， 2016， 96 (2): 85-90． ［15］中国医师协会呼吸医师分会. 合理应用抗流行性感冒病毒药物治疗流行性感冒专家共识（2016年)［J］. 中华内科杂志， 2016， 55 (3): 244-248.  ［16］中国中西医结合学会传染病专业委员会. 人禽流感中西医结合诊疗专家共识［J］. 中华传染病杂志，2016，34 (11): 641-647.  ［17］Lam TT, Wang J, Shen Y, et al. The genesis and source of the H7N9 influenza viruses causing human infections in China［J］. Nature, 2013, 502 (7470): 241-244.  ［18］姜慧, 于德山，阮峰，等. 中国10省（市）流感成年人住院病例的临床特征及重症危险因素分析［J］. 中华流行病学杂志， 2015， 36 (3): 216-221.  ［19］Pfitscher LC, Cecatti JG, Pacagnella RC, et al. Severe maternal morbidity due to respiratory disease and impact of 2009 H1N1 influenza A pandemic in Brazil: results from a national multicenter cross-sectional study［J］. BMC Infect Dis, 2016, 16: 220.  ［20］Katz MA, Gessner BD, Johnson J, et al. Incidence of influenza virus infection among pregnant women: a systematic review［J］. BMC Pregnancy Childbirth, 2017, 17(1): 192.  ［21］Feng L, Shay DK, Jiang Y, et al. Influenza-associated mortality in temperate and subtropical Chinese cities, 2003-2008［J］. Bull Word Health Organ, 2012, 90(4): 279-288B.  ［22］Fezeu L, Julia C, Henegar A, et al. Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis［J］. Obes Rev, 2011, 12(8): 653-659.  ［23］Segaloff HE. The impact of obesity and timely antiviral administration on severe influenza outcomes among hospitalized adults［J］. J Med Virol, 2018, 90(2): 212-218.  ［24］中国国家流感中心．流感监测周报［R／OL］ http://www.chinaivdc.cn/cnic/zyzx/lgzb/201706/t20170612_144031.htm.［2017-06-12］． ［25］Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study［J］. Lancet, 2007, 370(9593): 1137-1145.  ［26］Zhou F, Li H, Gu L, et al. Risk factors for nosocomial infection among hospitalized severe influenza A(H1N1) pdm09 patients［J］. Respir Med, 2018, 134: 86-91.  ［27］Chinese center for Disease Control and Prevention. Technical guidelines for the application of seasonal influenza vaccine in China(2014-2015) ［R］．Beijing, 2014． ［28］Uyeki TM. Preventing and Controlling Influenza with Available Interventions［J］. N Engl J Med, 2014, 370(9): 789-791. ［29］Lai S, Qin Y, Cowling BJ, et al. Global epidemiology of avian influenza A(H5N1) virus infection in humans, 1997-2015: a systematic review［J］. Lancet Infect Dis, 2016, 16(7): e108-e118.  ［30］Su S, Gu M, Liu D, et al. Epidemiology, Evolution, and Pathogenesis of H7N9 Influenza Viruses in Five Epidemic Waves since 2013 in China［J］. Trends Microbiol, 2017, 25(9): 713-728.  ［31］Sha J, Chen X, Ren Y, et al. Differences in the epidemiologyand virology of mild, severe and fatal human infections with avian influenza A (H7N9) virus［J］. Arch Virol, 2016, 161(5): 1239-1259.  ［32］Esteban YM, de Jong JLO, Tesher MS. An Overview of Hemophagocytic Lymphohistiocytosis［J］. Pediatr Ann, 2017, 46 (8): e309-e313.  ［33］Suzuki S, Tanaka A, Fukuda Y, et al. Successful Treatment of Seasonal Influenza A (H3N2) infection-related Hemophagocytic Lymphocytosis in an Elderly Man［J］. Kansenshogaku Zasshi, 2016, 90(1): 77-82. ［34］Henter JI, Chow CB, Leung CW, et al. Cytotoxic therapy for severe avian influenza A(H5N1) infection［J］. Lancet, 2006, 367 (9513): 870-873. ［35］Beutel G, Wiesner O, Eder M, et al．Vires-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection［J］. Crit Care, 2011, 15(2): R80. ［36］Schulert GS, Zhang M, Fall N, et al. Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza［J］. J Infect Dis, 2016, 213(7): 1180-1188.  ［37］Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders［J］. Hematology Am Soc Hematol Educ Program, 2009: 127-131.  ［38］Meijer WJ, Linn FH, Wensing AM, et al. Acute influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis［J］. JMM Case Rep, 2016, 3(6): e005076.  ［39］Mcswiney P, Pumama J, Komberg A, et al. A severe neurological complication of influenza in a previously well child［J］. BMJ Case Rep, 2014, pii: bcr2014206930.  ［40］Onitsuka H, Imamura T, Miyamoto N, et al. Clinical manifestations of influenza a myocarditis during the influenza epidemic of winter 1998-1999［J］. J Cardiol, 2001, 37(6): 315-323. ［41］Ito N, Sato M, Momoi N, et al. Influenza a H1N1 pdm09-associated myocarditis during zanamivir therapy［J］. Pediatr Int, 2015, 57 (6): 1172-1174． ［42］Ukimura A, Satomi H, Ooi Y, et al. Myocarditis associated with influenza A H1N1 pdm2009［J］. Influenza Res Treat, 2012, 2012: 351979. ［43］Wang J, Xu H, Yang X, et al. Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care［J］. Braz J Infect Dis, 2017, 21(1): 12-18. ［44］Warren-Gash C, Bhaskaran K, Hayward A, et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong［J］. J Infect Dis, 2011, 203(12): 1710-1718.  ［45］Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study［J］. J Infect Dis, 2012, 206(11): 1652-1659.  ［46］Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review［J］. Lancet Infect Dis, 2009, 9 (10): 601-610.  ［47］Sellers SA, Hagan RS, Hayden FG, et al. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection［J］. Influenza Other Respir Viruses, 2017, 11(5): 372-393.  ［48］Takayanagi N, Tokunaga D, Kubota M, et al. Community-acquired pneumonia with rhabdomyolysis［J］. Nihon Kokyuki Gakkai Zasshi, 2005, 43(12): 731-735． ［49］Fadila MF, Wool KJ. Rhabdomyolysis secondary to influenza infection: a case report and review of the literature［J］. N Am J Med Sci, 2015, 7 (3): 122-124.  ［50］Ishiguro T, Kagiyama N, Uozumi R, et al. Clinical Characteristics of Influenza-Associated Pneumonia of Adults: Clinical Features and Factors Contributing to Severity and Mortality［J］. Yale J Biol Med, 2017, 90(2): 165-181. ［51］McAlister VC. H1N1-related SIRS［J］. CMAJ, 2009, 181(9): 616-617.  ［52］Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA［J］. Lancet, 2009, 374(9688): 451-458.  ［53］Li J, Kou Y, Yu X, et al. Human Co-Infection with Avian and Seasonal Influenza Viruses, China［J］. Emerg Infect Dis, 2014, 20(11): 1953-1955.  ［54］Zhu Y, Qi X, Cui L, et al. Human co-infection with novel avian influenza A H7N9 and influenza A H3N2 viruses in Jiangsu province, China［J］. Lancet, 2013, 381(9883): 2134.  ［55］Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza［J］. Clin Infect Dis, 2019, 68(6): 895-902.  ［56］Cruz AT, Demmler-Harrison GJ, Caviness AC, et al. Performance of a rapid influenza test in children during the H1N1 2009 influenza a outbreak［J］. Pediatrics, 2010, 125: e645-e650.  ［57］Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: Clinical practice guidelines of the Infectious Diseases Society of America［J］. Clin Infect Dis, 2009, 48(8): 1003-1032.  ［58］Drexler JF, Helmer A, Kirberg H, et al. Poor clinical sensitivity of rapid antigen test for influenza a pandemic (H1N1) 2009 virus［J］. Emerg Infect Dis, 2009, 15(10): 1662-1664.  ［59］Gordon A, Videa E, Saborío S, et al. Diagnostic accuracy of a rapid influenza test for pandemic influenza A H1N1［J］. PLoS One, 2010, 5(4): e10364.  ［60］Diederen BM, Veenendaal D, Jansen R, et al. Rapid antigen test for pandemic (H1N1) 2009 virus［J］. Emerg Infect Dis, 2010, 16(5): 897-898.  ［61］Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) Virus-United States, 2009［J］. MMWR Morb Mortal Wkly Rep, 2009, 58(30): 826-829. ［62］Chartrand C, Leeflang MM, Minion J, et al. Accuracy of rapid influenza diagnostic tests: A meta-analysis［J］. Ann Intern Med, 2012, 156(7): 500-511.  ［63］Chen Y, Wang D, Zheng S, et al. Rapid diagnostic tests for identifying avian influenza A(H7N9) virus in clinical samples［J］. Emerg Infect Dis, 2015, 21(1): 87-90.  ［64］Ganzenmueller T, Kluba J, Hilfrich B, et al. Comparison of the performance of direct fluorescent antibody staining, a point-of-care rapid antigen test and virus isolation with that of RT-PCR for the detection of novel 2009 influenza A (H1N1) virus in respiratory specimens［J］. J Med Microbiol, 2010, 59(Pt 6): 713-717.  ［65］Wang XR, Gu LL，Shi JZ，et al. Development of a real-time RT-PCR method for the detection of newly emerged highly pathogenic H7N9 influenza viruses ［J］. Journal of Integrative Agriculture, 2017, 16 (9): 2055-2061.  ［66］Wu ZQ, Zhang Y, Zhao N, et al. Comparative Epidemiology of Human Fatal Infections with Novel, High (H5N6 and H5N1) and Low (H7N9 and H9N2) Pathogenicity Avian Influenza A Viruses［J］. Int J Environ Res Public Health, 2017, 14(3). pii: E263.  ［67］Trampuz A, Prabhu RM, Smith TF, et al. Avian influenza: a new pandemic threat［J］. Mayo Clin Proc, 2004, 79(4): 523-530; quiz 530.  ［68］Centers for Disease Control and prevention. Influenza (Seasonal). Guide for considering influenza testing when influenza viruses are circulating in the community［EB/OL］. ［2017-12-28］. https://www.cdc.gov/flu/professionals/diagnosis/consider-influenza-testing.htm ［69］Centers for Disease Control and prevention. Influenza avian Interim Guidance on Case Definitions for Investigations of Human Infection with Avian Influenza A (H7N9) Virus in the United States［EB/OL］. ［2017-12-28］. https://www.cdc.gov/flu/avianflu/h7n9/case-definitions.htm ［70］Leung YH, To MK, Lam TS, et al. Epidemiology of human influenza A(H7N9) infection in Hong Kong［J］. J Microbiol Immunol Infect, 2017, 50(2): 183-188.  ［71］Seymour CW. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)［J］. JAMA, 2016, 315(8): 762-774.  ［72］Sahasrabhojney V, Game PD, Chand D, et al. SpO2/FiO2 ratio: a prognostic marker for influenza patients［J］. Int J Res Med Sci, 2015, 3(12): 3830-3832.  ［73］Wang Y, Quo Q, Yan Z, et al. Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A (H7N9) Virus Infection［J］. J Infect Dis, 2018, 217(11): 1708-1717.  ［74］Beigel JH, Bao Y, Beeler J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicenter double-blind, randomized phase 2 trial［J］. Lancet Infect Dis, 2017, 17(12): 1255-1265.  ［75］Muthuri SG, Venkatesan S, Myles PR， et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data［J］. Lancet Respir Med, 2014, 2(5): 395-404.  ［76］Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomized controlled trials［J］. Lancet, 2015, 385(9979): 1729-1737. ［77］Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry［J］. J Infect Dis, 2010, 202(8): 1154-1160.  ［78］CDC. 2008-2009 Influenza Season Week 38 ending September 26, 2009. Centers for Disease Control and Prevention， 2009a. ［79］Matsuzaki Y, Mizuta K, Aoki Y, et al. A two-year survey of the oseltamivir-resistant influenza A (H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir［J］. Virol J, 2010, 7: 53. ［80］Pizzorno A, Abed Y, Boivin G. Influenza drug resistance［J］. Semin Respir Crit Care Med, 2011, 32(4): 409-422.  ［81］Pizzorno A, Bouhy X, Abed Y, et al. Generation and characterization of recombinant pandemic influenza A (H1N1) viruses resistant to neuraminidase inhibitors［J］. J Infect Dis, 2011, 203(1): 25-31.  ［82］黄维娟，谭敏菊，李希妍，等. 2013～2017 年中国大陆流行的 A (H3N2) 亚型流感病毒对神经氨酸酶抑制剂的敏感性分析［J］. 病毒学报，2018，6: 793-799. ［83］Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection［J］. Antimicrob Agents Chemother, 2011, 55(11): 5267-5276.  ［84］Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies［J］. Ann Intern Med, 2012, 156(7): 512-524. ［85］Cole JA, Loughlin JE, Ajene AN, et al. The effect of zanamivir treatment on influenza complications: A retrospective cohort study［J］. Clin Ther, 2002, 24(11): 1824-1839. ［86］Public Health England (2019) PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. Version 9.1, January 2019. ［87］Chartrand C, Leeflang MM, Minion J, et al. Accuracy of rapid influenza diagnostic tests: a-meta analysis［J］. Ann Intern Med, 2012, 156(7): 500-511. ［88］陈晓蓉，杨宗国，陆云飞，等. 人感染H7N9禽流行性感冒的中西医结合治疗及预后分析［J］. 中华传染病杂志，2014，32(1): 26-30. ［89］于斌，陈佳，厉启芳 , 等. 清热解毒药物治疗流行性感冒疗效的meta分析［J］. 中国医院药学杂志， 2013， 33(17): 1451-1454. ［90］蔡林利，蒋红丽，樊涛，等. 连花清瘟胶囊治疗流行性感冒疗效和安全性的系统评价［J］. 中国循证医学杂志，2012，12(11): 1396-1403.  ［91］宣文. 关于应用中医药防治人感染高致病性H5N1 禽流感的可行性分析［J］. 上海中医药杂志， 2006， 40(1): 18-19. ［92］马羽萍，郭雅玲，康立, 等. 中药治疗甲型H1N1流感疗效分析［J］. 陕西中医, 2010, 31(10): 1351-1353.  ［93］Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial［J］. Ann Intern Med, 2011, 155(4): 217-225.  ［94］Liu Y, Mu W, Xiao W, et al. Efficacy and safety of Re-Du-Ning injection in the treatment of seasonal influenza: results from a randomized, double-blinded, multicenter, oseltamivir-controlled trial［J］. Oncotarget, 2017, 8(33): 55176-55186.  ［95］Okada T, Morozumi M, Matsubara K, et al. Characteristic findings of pediatric inpatients with pandemic (H1N1) 2009 virus infection among severe and non severe illnesses［J］. J Infect Chemother, 2011, 17(2): 238-245.  ［96］Sposato B, Croci L, Canneti E, et al. Influenza A H1N1 and severe asthma exacerbation［J］. Eur Rev Med Pharmacol Sci, 2010, 14(5): 487-490. ［97］中国医师协会急诊医师分会，中国急诊感染联盟. 2015年中国急诊社区获得性肺炎临床实践指南——治疗和预后篇［J］. 中国急救医学， 2016， 36(1): 12-21. ［98］孙兰，刘艾林，王振中，等.热毒宁注射液及其组分对流感病毒神经氨酸酶的抑制作用研究［J］. 现代药物与治疗, 2014, 29(1): 27-31.  ［99］Nakamura M, Yamanaka G, Kawashima H, et al. Clinical Application of Rapid Assay of Interleukin-6 in Influenza-Associated Encephalopathy［J］. Dis Markers, 2005, 21(4): 199-202. ［100］Alsolami A, Shiley K. Successful Treatment of Influenza-Associated Acute Necrotizing Encephalitis in an Adult Using High-Dose Oseltamivir and Methylprednisolone: Case Report and Literature Review［J］. Open Forum Infect Dis, 2017, 4(3): ofx145.  ［101］Bergamino L, Capra V, Biancheri R, et al. Immunomodulatory therapy in recurrent acute necrotizing encephalopathy ANE1: is it useful［J］. Brain Dev, 2012, 34(5): 384-391.  ［102］Tabarki B, Thabet F, Al Shafi S, et al. Acute necrotizing encephalopathy associated with enterovirus infection［J］. Brain Dev, 2013, 35(5): 454-457.  ［103］Choi SM, Boudreault AA, Xie H, et al．Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients［J］. Blood, 2011, 117(19): 5050-5056. ［104］Quispe-Laime AM, Bracco JD, Barberio PA, et al．H1N1 influenza A virus-associated acute lung injury:Response to combination oseltamivir and prolonged corticosteroid treatment［J］. Intensive Care Med, 2010, 36(1): 33-41. ［105］Cao B, Gao H, Zhou B, et al. Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia［J］. Crit Care Med, 2016, 44(6): e318-328.  ［106］Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroi: the Guangzhou experience［J］. Chest, 2006, 129 (6): 1441-1452. ［107］刘凯雄，瞿介明. 糖皮质激素在甲型H1N1流感中的应用探讨［J］. 中国呼吸与危重监护杂志， 2010， 9(3): 226-227.  ［108］Dunstan HJ, Mill AC, Stephens S, et al. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study［J］. BJOG, 2014, 121(7): 901-906. ［109］Wollenhaupt M, Chandrasekaran A, Tomianovic D. The safety of osehamivir in pregnancy: an updated review of post-marketing data［J］. Pharmacoepidemiol Drug Saf, 2014, 23(10): 1035-1042. ［110］Centers for Disease Control and prevention. Avian Influenza. Interim Guidance for Infection Control within Healthcare Settings When Caring for Confirmed Cases, Probable Cases, and Cases under Investigation for Infection with Novel Influenza A Viruses Associated with Severe Disease. https://www.cdc.gov/flu/avianflu/novel-flu-infection-control.htm ［111］Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season［J］. MMWR Recomm Rep, 2018, 67(3): 1-20. ［112］冯录召，彭质斌，王大燕，等. 中国流感疫苗预防接种技术指南(2018-2019)［J］. 中华预防医学杂志， 2018， 52(11): 1101-1114. ［113］Osterholm MT, Kelley NS, Sommer A, et al. Efficacy andeffectiveness of influenza vaccines: a systematic review and meta-analysis［J］. Lancet Infect Dis, 2012, 12(1): 36-44. ［114］Singh RK, Dhama K, Karthik K, et al. A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies［J］. Front Microbiol, 2018, 9: 1941. ［115］Barregard L, Rek D, Horvat M, et al. Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine［J］. Toxicol Sci, 2011, 120(2): 499-506.